Stableford Capital II LLC Invests $1.28 Million in Definium Therapeutics, Inc. $DFTX

Key Points

• Stableford Capital II acquired 27,141 shares of Definium Therapeutics worth approximately $1.28 million in the second quarter. Institutional investors collectively own 27.91% of the company, with several major funds also initiating or increasing positions.
• Wall Street sentiment remains positive, with the stock carrying a consensus “Buy” rating and an average price target of $63. Analysts’ targets range from $52 to $75.
• Definium reported quarterly EPS of -$1.44, missing the consensus estimate of -$0.55. The stock opened at $38.23, compared with a 52-week range of $8.77 to $49.70, while insiders sold $2.89 million worth of shares over the past three months.

Stableford Capital II LLC acquired a new position in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,141 shares of the company's stock, valued at approximately $1,277,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new position in shares of Definium Therapeutics in the second quarter worth about $283,999,000. Avoro Capital Advisors LLC acquired a new stake in Definium Therapeutics in the fourth quarter valued at approximately $66,950,000. Commodore Capital LP raised its stake in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock worth $32,450,000 after buying an additional 475,000 shares during the period. Wellington Management Group LLP purchased a new position in shares of Definium Therapeutics during the 2nd quarter valued at approximately $138,755,000. Finally, Janus Henderson Group PLC grew its stake in Definium Therapeutics by 8,513.2% in the 4th quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company's stock valued at $32,256,000 after acquiring an additional 2,383,696 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an "outperform" rating in a research note on Monday, June 22nd. Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the company a "buy" rating in a report on Friday, August 14th. Finally, Needham & Company LLC raised their target price on Definium Therapeutics from $50.00 to $66.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Definium Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $63.00.

Insider Activity

In other news, insider Mark Sullivan sold 13,008 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. This trade represents a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 67,119 shares of company stock valued at $2,887,496 over the last three months. 2.40% of the stock is currently owned by company insiders.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $38.23 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The stock's fifty day moving average is $43.35 and its two-hundred day moving average is $29.88. The firm has a market capitalization of $5.14 billion, a P/E ratio of -11.15 and a beta of 2.23. Definium Therapeutics, Inc. has a fifty-two week low of $8.77 and a fifty-two week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.